| HOME >> BIOLOGY >> TECHNOLOGY |
(i) Tax effect on adjustments as discussed above in notes (b), (c), (d),
(f) and (h).
(j) For the three months ended December 31, 2007, potential dilutive
shares were not used in the calculation of diluted net loss per
common share under GAAP because inclusion thereof would be
antidilutive.
(k) Included in the weighted average diluted common shares for the
calculation of diluted net income per common share for the three
months ended December 31, 2007, on an adjusted cash basis, are
dilutive shares consisting of 4,053,000 common stock equivalent
shares from the potential exercise of stock options and awards and
warrants. The diluted net income per common share calculation for
the three months ended December 31, 2007, on an adjusted cash
basis, does not include 2,868,000 common stock equivalent shares
from the potential conversion of convertible debt, as inclusion
thereof would be antidilutive.
(l) Included in the weighted average diluted common shares for the
calculation of diluted net income per common share for the three
months ended December 31, 2006, under GAAP and on an adjusted cash
basis, are dilutive shares consisting of 1,830,000 common stock
equivalent shares from the potential exercise of stock options and
warrants.
Inverness Medical Innovations, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and
Reconciliation to Non-GAAP Adjusted Cash Basis Amounts
(in $000s, except per share amounts)
Year Ended December 31, 2007
Non-GAAP
A
'/>"/>
| SOURCE Inverness Medical Innovations Copyright©2008 PR Newswire. All rights reserved |